Rocket Lab Fans Shocked: Betting on Promises Isn’t an Investment Strategy

So Rocket Lab (NASDAQ: RKLB) announced a manufacturing defect in Neutron, the stock dropped, and Motley Fool responded with a “video” teasing what the delay “could mean.” A video. About a hypothetical. Let’s do what the video apparently didn’t: math.

Here’s what we actually know. A defect was found. Neutron’s timeline slips. Costs rise. That’s it. Everything else—the revenue models, the TAM projections, the “Rocket Lab is the next SpaceX” takes—is spreadsheet fiction built on a rocket that hasn’t flown yet. If your investment thesis for RKLB requires Neutron to hit its original schedule, you didn’t have a thesis. You had a wish.

And yet people keep anchoring on the promise instead of the track record. Electron is small-lift, a market with thin margins and modest pricing power. Neutron is the entire bull case: medium-lift, reusable ambitions, and—critically—competing against SpaceX’s Falcon 9, a rocket with a launch cadence and cost structure no one has matched in a decade. “But SpaceX was unprofitable early too” is not analysis, it’s survivorship bias with a logo. For every SpaceX there’s a graveyard of well-funded launch companies that burned investor capital producing spectacular fireworks.

Run the opportunity cost. Money parked in RKLB waiting for a rocket that keeps slipping is money not compounding in a boring, low-fee index fund at historical market returns. Delay the timeline by two years and your position needs the eventual payoff to be dramatically larger just to break even against what you forwent. Add dilution—the predictable companion of pre-revenue-scale development programs slipping schedules—and shareholders aren’t just waiting, they’re being watered down while they wait.

If you still want exposure, size it like the speculative bet it is: a slice of your portfolio you can watch go to zero without altering your savings rate or FIRE date. Your financial independence should never depend on a rocket engine’s metallurgy. If it does, you’ve confused investing with lottery tickets that come with an investor relations page.

The defect itself may be routine. Aerospace is hard; delays are the industry’s native currency. What’s not routine is treating every “could mean” headline as due diligence. The market will tell you what RKLB is worth when Neutron flies—or doesn’t. Until then, the most reliable launch vehicle in your portfolio should be your savings rate.